Abstract
Cytokines constitute a large group of macromolecules which mediate the development, activation and/or function of the various components of the immune system. This system may have beneficial effects as an essential instrument of defense against foreign microorganisms or transformed neoplastic cells, but it may also have deleterious effect in the pathogenesis of several types of autoimmune diseases. As the finely tuned mechanisms of immune activation and action are typified by their multiplicity and the diversity of their characteristics, they offer unique opportunities for selective pharmacological and immunopharmacological intervention. In this short article, four examples are briefly discussed which illustrate aspects of regulation of cytokine function in target cells (Mantovani), the cooperative role of cytokines in cell differentiation (Mertelsmann), the induction of certain cytokines by biological response modifiers (Schreiber), and the clinical application of anti-TNF (Tumor Necrosis Factor) “humanized” antibodies in Rheumatoid arthritis (Feldman).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Colotta F, Sironi M, Borre A, Pollicino T, Bernasconi S, Boraschi D, et al. Type II interleukin-1 receptor is not expressed in cultured endothelial cells and is not involved in endothelial cell activation. Blood 1993; 81(5): 1347–1351.
Munoz E, Zubiaga AM, Sims JE, Huber BT. J. IL-1 signal transduction pathways. I. two functional IL-1 receptors are expressed in T cells. J. Immunol. 1991; 146: 136–143.
Eastgate JA, Symons JA, Duff GW. Identification of an interleukin-1 beta binding protein in human plasma. FEBS Lett. 1990; 260(2): 213–216.
Mandila J, Ikejima T, Dinarello CA. Glycosylation of the interleukin-1 receptor type I is required for optimal binding of interleukin-1. Lymphokine & Cytokine Res. 1992; 114: 197–205.
Colotta F, Dower SK, Sims JE, Mantovani A. The type II ‘decoy’ receptor: a novel regulatory pathway for interleukin 1. Immunol. Today 1994; 15(12): 562–556.
Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigen cancer cells. J. Exp. Med. 1992; 175: 139–146.
Teng MN, Park BH, Koeppen HKW, Tracey KJ, Fendly BM, Schreiber H. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc. Natl. Acad. Sci. USA 1991; 88: 3535–3539.
Teng MN, Turksen K, Jacobs CA, Fuchs E, Schreiber H. Prevention of runting and cachexia by a chimeric TNF receptor-Fc protein. Clinical Immunol. And Immunopath 1993; 69: 215–222.
Pekarek LA, Weichselbaum RR, Beckett MA, Nachman J, Schreiber H. Footprinting of individual tumors and their variants by constitutive cytokine expression patterns. Cancer Res. 1993; 53: 1978–1981.
Pekarek LA, Starr BA, Weichselbaum RR, Toledano AY, Schreiber H. (submitted) Inhibition of tumor growth by elimination of granulocytes.
Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL1α. Clin Exp. Immunol 1988; 73: 449–455.
Portillo G, Turner M, Chantry D, Feldmann M. Effects of cytokines on HLA-DR and IL-1 production by a monocyte tumour, THP-1. Immunol. 1989; 66: 170–175.
Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244–247.
Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur. J. Immunol. 1991; 21: 2575–2579.
Alvaro-Garcia JM, Zvaifler NJ, Brown CB, Kaushansky L, Firestein GS. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and TNF-alpha. J. Immunol. 1991; 146: 3365–3371.
Kowanko IC, A F. Granulocyte macrophage colony-stimulating factor augments neutrophil-mediated cartilage degradation and neutrophil adherence. Arthritis Rheum. 1991; 11: 1452–1460.
Keffer J, Probert LHC, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991; 10: 5025–4031.
Arend W. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J. Clin. Invest 1991; 5: 1445–1451.
Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991; 5: 2567–2574.
Roux-Lombard P, Modoux C, Vischer T, Grassi J, Dayer JM. Inhibitors of interleukin 1 activity in synovial fluids and in cultured synovial fluid mononuclear cells. J. Rheumatol 1992; 19: 517–523.
Cope AP, Aderka D, Doherty M, Englemann H, Gibbons D, Jones AC et al. Increased levels of soluble tumor necrosis factor receptros in the sera and synovial fluid patients with rheumatic diseases. Arthritis Rheum. 1992; 35: 1160–1169.
Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα. Arthritis Rheum. 1993; 36: 1681–1690.
Elliot MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smollen JS et al. Treatment with a chimaeric monoclonal antibody to tumour necrosis factor α suppresses disease activity in rheumatoid arthritis. Lancet 1994; 344: 1105–1110.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Mantovani, A., Mertelsman, R., Schreiber, H., Feldmann, M., Mihich, E. (1995). Selected Aspects of the Immunopharmacology of Cytokines. In: Cuello, A.C., Collier, B. (eds) Pharmacological Sciences: Perspectives for Research and Therapy in the Late 1990s. Birkhäuser Basel. https://doi.org/10.1007/978-3-0348-7218-8_38
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7218-8_38
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-0348-7220-1
Online ISBN: 978-3-0348-7218-8
eBook Packages: Springer Book Archive